Drugs / Peginterferon Alfacon-2
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06544551 | Dec 2021 → Nov 2023 | chronic hepatitis B virus infection | Beijing Kawin Technology Share-Holding Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peginterferon Alfacon-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06544551 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL6068082 ↗ |
| Route | Subcutaneous | “Peginterferon Alfacon-2 injection will be weekly subcutaneous injected for 48 weeks.” NCT06544551 ↗ |